EDG-5506
Sponsors
Edgewise Therapeutics Inc., Edgewise Therapeutics, Inc.
Conditions
Becker Muscular DystrophyBecker Muscular Dystrophy (BMD)Healthy VolunteerLimb-Girdle Muscular DystrophyMcArdle DiseaseMuscular Dystrophies
Phase 1
A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults
CompletedNCT04585464
Start: 2020-10-12End: 2021-12-27Updated: 2022-06-28
A Study to Assess the Feasibility of Non-invasive Dried Blood Sampling
CompletedNCT05492734
Start: 2022-08-12End: 2022-08-19Updated: 2022-09-02
Phase 2
A Phase 2 Randomized, Double-blind, Placebo-controlled Study of the Effect of EDG-5506 on Biomarker Response to Exercise in Adults with Becker Muscular Dystrophy, McArdle Disease, or Limb-Girdle Muscular Dystrophy
CompletedCTIS2022-500215-39-00
Start: 2022-12-06End: 2025-11-24Target: 21Updated: 2025-09-19
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of EDG-5506 on Safety, Biomarkers, Pharmacokinetics, and Functional Measures in Adults and Adolescents with Becker Muscular Dystrophy
Active, not recruitingCTIS2022-500090-13-00
Start: 2022-12-29Target: 81Updated: 2025-09-12
An Open-Label Extension Study to Assess the Long-term Effect of EDG-5506 on Safety, Biomarkers, and Functional Measures in Adults and Adolescents with Becker Muscular Dystrophy
RecruitingCTIS2023-506231-15-00
Start: 2024-02-22Target: 85Updated: 2025-10-15